News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaDel Pharma (NVD) Announces the Signing of a Definitive Agreement to Sell Its NovaMist™ Technology and Certain Other Assets


4/8/2013 9:52:17 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (NVDL.PK) has signed a definitive agreement to sell its NovaMist™ technology and certain other assets to SUDA LTD, an Australian publicly held pharmaceutical company. The transaction includes the sale of NovaDel’s patents and trademarks relating to its NovaMist technology. The sale, as contemplated, does not include the NitroMist® or ZolpiMist™ intellectual property or licenses. Subject to shareholder approval, NovaDel will receive at closing $400,000 in cash, 50,000,000 shares of SUDA Common stock and 10,000,000 options for the purchase of SUDA Common shares at $0.05 per share. It is the Company’s intention to use part of the proceeds from this sale, after transaction expenses, to reduce its outstanding liabilities.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES